Qingyun K. Wu

West Huaihai Road
Xuzhou, 221002, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 52 publications

Best Evidence for Life-Sustaining Treatment Decision-Making Assessment in Hospitalized Adults with Advanced Cancer in Chinese Clinical Practice.

Best Evidence for Life-Sustaining Treatment Decision-Making Assessment in Hospitalized Adults with Advanced Cancer in Chinese Clinical Practice.

Journal: Journal of visualized experiments : JoVE

Published: September 04, 2026

Allo-HSCT Might Improve Long-Term Survival in Patients with CD56-Positive AML.

Allo-HSCT Might Improve Long-Term Survival in Patients with CD56-Positive AML.

Journal: Journal of blood medicine

Published: February 08, 2026

Application of NeoVI-RADS scoring in patients with bladder cancer undergoing neoadjuvant therapy

Application of NeoVI-RADS scoring in patients with bladder cancer undergoing neoadjuvant therapy

Journal: Zhonghua wai ke za zhi [Chinese journal of surgery]

Published: November 11, 2025

Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.

Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.

Journal: International urology and nephrology

Published: November 20, 2024

Glycosyltransferase B4GALNT1 promotes immunosuppression in hepatocellular carcinoma via the HES4-SPP1-TAM/Th2 axis.

Glycosyltransferase B4GALNT1 promotes immunosuppression in hepatocellular carcinoma via the HES4-SPP1-TAM/Th2 axis.

Journal: Molecular biomedicine

Published: June 28, 2024

Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma.

Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma.

Journal: Cytotherapy

Published: May 06, 2024

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.

Journal: Nature communications

Published: January 24, 2024

Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects.

Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 inhibitors: Research progress and prospects.

Journal: European journal of medicinal chemistry

Published: November 13, 2023

Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.

Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy.

Journal: Cytotherapy

Published: October 22, 2023

Design, synthesis and biological evaluation of MNK-PROTACs.

Design, synthesis and biological evaluation of MNK-PROTACs.

Journal: Molecular diversity

Published: October 10, 2023

The Association between Dietary Habits and Rapid Postoperative Recovery of Rotator Cuff Repair.

The Association between Dietary Habits and Rapid Postoperative Recovery of Rotator Cuff Repair.

Journal: Nutrients

Published: September 14, 2023

Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy.

Long-term analysis of cellular immunity in patients with RRMM treated with CAR-T cell therapy.

Journal: Clinical and experimental medicine

Published: August 11, 2023

Showing 1-12 of 52

Last Updated: 09/26/2026